PURPOSE: Transforming growth factor β1 (TGFβ1), TGFβ receptor (TGFβR2), and connective tissue growth factor (CTGF) are key regulators of fibrosis in the cornea and in other tissues, including liver, skin, and kidney. We developed an antifibrotic treatment targeting these three critical scarring genes by using a combination of small interfering RNAs (siRNAs) and assessed its effect on downstream scarring genes, collagen I, and α smooth muscle actin (SMA). METHODS: Up to six individual siRNAs for each of the three target gene mRNAs were transfected into cultures of rabbit corneal fibroblasts at concentrations from 15 to 90 nM. The knockdown of target gene proteins was measured by ELISA, and the two most effective siRNAs were tested in dual combinations. Knockdown percentages of both individual and dual siRNA combinations were analyzed for synergy by using combination index to predict "effective" and "ineffective" triple siRNA combinations. Effects of both triple siRNA combinations on target and downstream mRNAs were measured by using quantitative RT-PCR, and levels of SMA protein were assessed by immunohistochemistry. RESULTS: Single and dual siRNA combinations produced a wide range of protein knockdown of target genes (5%-80%). The effective triple siRNA combination significantly reduced mRNA levels of target genes (>80%) and downstream scarring genes (>85%), and of SMA protein (>95%), and significantly reduced cell migration without reducing cell viability. CONCLUSIONS: Simultaneous targeting of TGFβ1, TGFβR2, and CTGF genes by effective triple siRNA combination produced high knockdown of target and downstream scarring genes without cell toxicity, which may have clinical applications in reducing corneal fibrosis and scarring in other tissues.
PURPOSE: Transforming growth factor β1 (TGFβ1), TGFβ receptor (TGFβR2), and connective tissue growth factor (CTGF) are key regulators of fibrosis in the cornea and in other tissues, including liver, skin, and kidney. We developed an antifibrotic treatment targeting these three critical scarring genes by using a combination of small interfering RNAs (siRNAs) and assessed its effect on downstream scarring genes, collagen I, and α smooth muscle actin (SMA). METHODS: Up to six individual siRNAs for each of the three target gene mRNAs were transfected into cultures of rabbitcorneal fibroblasts at concentrations from 15 to 90 nM. The knockdown of target gene proteins was measured by ELISA, and the two most effective siRNAs were tested in dual combinations. Knockdown percentages of both individual and dual siRNA combinations were analyzed for synergy by using combination index to predict "effective" and "ineffective" triple siRNA combinations. Effects of both triple siRNA combinations on target and downstream mRNAs were measured by using quantitative RT-PCR, and levels of SMA protein were assessed by immunohistochemistry. RESULTS: Single and dual siRNA combinations produced a wide range of protein knockdown of target genes (5%-80%). The effective triple siRNA combination significantly reduced mRNA levels of target genes (>80%) and downstream scarring genes (>85%), and of SMA protein (>95%), and significantly reduced cell migration without reducing cell viability. CONCLUSIONS: Simultaneous targeting of TGFβ1, TGFβR2, and CTGF genes by effective triple siRNA combination produced high knockdown of target and downstream scarring genes without cell toxicity, which may have clinical applications in reducing corneal fibrosis and scarring in other tissues.
Authors: Aimee L Jackson; Julja Burchard; Janell Schelter; B Nelson Chau; Michele Cleary; Lee Lim; Peter S Linsley Journal: RNA Date: 2006-05-08 Impact factor: 4.942
Authors: G Westergren-Thorsson; J Hernnäs; B Särnstrand; A Oldberg; D Heinegård; A Malmström Journal: J Clin Invest Date: 1993-08 Impact factor: 14.808
Authors: Anna L Mead; Tina T L Wong; M Francesca Cordeiro; Ian K Anderson; Peng T Khaw Journal: Invest Ophthalmol Vis Sci Date: 2003-08 Impact factor: 4.799
Authors: W A Border; N A Noble; T Yamamoto; J R Harper; Y u Yamaguchi; M D Pierschbacher; E Ruoslahti Journal: Nature Date: 1992-11-26 Impact factor: 49.962
Authors: M F Cordeiro; A Mead; R R Ali; R A Alexander; S Murray; C Chen; C York-Defalco; N M Dean; G S Schultz; P T Khaw Journal: Gene Ther Date: 2003-01 Impact factor: 5.250
Authors: Daniela Castanotto; Kumi Sakurai; Robert Lingeman; Haitang Li; Louise Shively; Lars Aagaard; Harris Soifer; Anne Gatignol; Arthur Riggs; John J Rossi Journal: Nucleic Acids Res Date: 2007-07-26 Impact factor: 16.971
Authors: Steven A Castleberry; Alexander Golberg; Malak Abu Sharkh; Saiqa Khan; Benjamin D Almquist; William G Austen; Martin L Yarmush; Paula T Hammond Journal: Biomaterials Date: 2016-04-14 Impact factor: 12.479
Authors: Sriniwas Sriram; Jennifer A Tran; Xiaoqing Guo; Audrey E K Hutcheon; Andrius Kazlauskas; James D Zieske Journal: Exp Eye Res Date: 2017-06-06 Impact factor: 3.467
Authors: Sriniwas Sriram; Jennifer A Tran; Xiaoqing Guo; Audrey E K Hutcheon; Hetian Lei; Andrius Kazlauskas; James D Zieske Journal: Invest Ophthalmol Vis Sci Date: 2017-02-01 Impact factor: 4.799